A randomized, double-blind, single dose comparison of pharmacokinetics and safety of FKB238 with bevacizumab.

Kaito, H; van den Berg, F; Niewiarowski, A; Boyce, M

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):